Illustration of our cloud-based HTDocking server to predict potential targets (pink nodes) and cross-targets (yellow, green and blue nodes) of compounds and to explore possible mechanisms. (A) The predicted targets of six known abused/approved drugs (opioids: codeine and DB01532; benzodiazepines: bromazepam and alprazolam; barbiturates: secobarbital and pentobarbital). (B) The predicted targets of 3 approved drugs for DA treatments (methadone, naltrexone, and buprenorphine). MAPK10, Mitogen-Activated Protein Kinase 10; CYP2A6, cytochrome P450, family 2, subfamily A, polypeptide 6; RAB6A, RAB6A, member RAS oncogene family; PBRM1, polybromo 1; PDE5A, phosphodiesterase 5A, cGMP-specific; A4, amyloid beta protein; RB1, retinoblastoma 1; MAPK14, mitogen-activated protein kinase 14; ALDR, Aldose reductase; PPARg, Peroxisome proliferator-activated receptor gamma; GABRA(1-6):Gamma-aminobutyric acid receptor subunit alpha-(1-6); MAOB, Monoamine Oxidase B; MAP2K1(5), Mitogen-Activated Protein Kinase 1(5); LCK, Tyrosine-protein kinase Lck; ESR1, Estrogen receptor; CTDS2, Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2; GRB14, Growth factor receptor-bound protein 14; GLR2, AMPA-selective glutamate receptor 2; ALDOA, Fructose-bisphosphate aldolase A; CA2, Carbonic anhydrase II; OPRD (OPRM,OPRK), Delta (Mu, Kappa)-type opioid receptor; AA2AR, Adenosine receptor A2a; MDR1, Multidrug resistance protein 1; GARS, Glycine-tRNA ligase.